drug delivery system 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源...
Post on 22-Dec-2015
259 views
TRANSCRIPT
![Page 1: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/1.jpg)
Drug Delivery System藥物投遞系統
生科系 04級 黃玫璇 891672生科系 04 級 許哲源 891659生科系 04 級 蕭宏展 891631生科系 04 級 楊淳竣 891625
![Page 2: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/2.jpg)
藥物投遞系統 (Drug Delivery System)
【必要時將必要限度藥物對必要部位之供應】
2. 市場分析 3. 公司簡介
1. 原理
目標導向(Target)
傳輸(Transport)
控釋(Controlled Release)
![Page 3: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/3.jpg)
藥物釋控系統
黃玫璇 891672
![Page 4: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/4.jpg)
藥物釋控系統
1. 何謂藥物釋控
2. 發展釋控的優點
3. 藥物釋控的種類
A. Diffusion controlled
B. Chemically controlled
C. Solvent-activated controlled
![Page 5: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/5.jpg)
藥物釋控系統
1. 何謂藥物釋控
2. 發展釋控的優點
3. 藥物釋控的種類
A. Diffusion controlled
B. Chemically controlled
C. Solvent-activated controlled
![Page 6: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/6.jpg)
【藥物釋控】: Drug Controlled Release System
將藥物以特殊的化學包覆,讓藥物在某一種狀態 (如 PH 值改變 )下適時 (ex: 延長 ) 適量釋出。
這種控釋劑型的技術發展,目前廣泛地應用於一般的製藥化學工業中。
![Page 7: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/7.jpg)
藥物釋控系統
1. 何謂藥物釋控
2. 發展釋控的優點
3. 藥物釋控的種類
A. Diffusion controlled
B. Chemically controlled
C. Solvent-activated controlled
![Page 8: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/8.jpg)
Potential Advantages of Controlled Release Systems
1. maintenance of drugs at therapeutically desirable levels
2. the ability to localize drugs to target organs to minimize systemic effects
3. improved patient compliance
4. protection from degradation for drugs with short in vivo lifetimes.
![Page 9: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/9.jpg)
Controlled Release vs. Single Dose
Time
Co
nc
en
tra
tio
n
Single Dosages
Controlled Release
Side Effects
Therapeutic DoseDesiredRange
![Page 10: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/10.jpg)
藥物釋控系統
1. 何謂藥物釋控
2. 發展釋控的優點
3. 藥物釋控的種類
A. Diffusion controlled
B. Chemically controlled
C. Solvent-activated controlled
![Page 11: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/11.jpg)
Types of Controlled Release Devices
【 Diffusion controlled 】 Diffusion through membrane or bulk polymer
【 Chemically controlled 】 ˙ polymer erosion : surface erosion, bulk erosion ( combination of erosion and diffusion ) ˙ pendent chain
【 Solvent-activated controlled 】 ˙ osmotic transport of water through semi permeable membrane ˙ water penetration into glassy polymer
![Page 12: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/12.jpg)
1.Diffusion controlled
【 Stomach/Intestine – Liquid 】【 Capsule edge – Gel 】
• Biocompatible polymer
【 Capsule center – Dry 】 • Allows for delayed release
△ release rates are determined by polymer property and partition coefficient of the drug to be released.
△advantage
˙ drug diffuses out of matrix at defined rate
△disadvantage
˙ efficiency of diffusion of large molecules
˙ danger of ‘dose dumping’ in barrier systems
![Page 13: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/13.jpg)
2.Chemically controlled
˙ erosion : Surface erosion, Bulk erosion
△ capsule is eroded by the acids in the stomach
△ advantage
˙ inject able (micro spheres)
˙ biodegradable (need not be removed surgically)
△ disadvantage
˙ difficult to stop once injected
![Page 14: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/14.jpg)
2.Chemically controlled
˙ pendent chain
△ drug is covalently bound to the polymer and is released by
bond scission owing to water or enzymes
![Page 15: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/15.jpg)
3. Solvent-activated controlled
△ the active agent is dissolved or dispersed within a polymeric matrix and is not able to diffuse through that matrix. △ advantage ˙ complex control △ disadvantage ˙ generally more bulky devices and require implantation
![Page 16: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/16.jpg)
Biodegradable Polymers
![Page 17: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/17.jpg)
![Page 18: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/18.jpg)
Application
![Page 19: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/19.jpg)
Targeting moiety for cell
891659 許哲源
![Page 20: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/20.jpg)
Introduction
• For the past several decades, researchers and clinicians have been using drugs and radiation to kill tumor cells.
• The chemotherapy and radiotherapy are only semiselective for malignant cells.
• In contrast, targeting drug therapy has the potential for greater specificity.
• With the advent of monoclonal antibody (MoAb) technology, researcher have been able to target different agents to target cells more effectively.
Pharmacol. Ther. 1994, 64:127–54
![Page 21: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/21.jpg)
EPR effect
• The Enhanced Permeability and Retention effect in tumor tissue
• Tumor cells show a higher degree of uptake of macromolecules by endocytosis than normal cell.
Microvasc. Res. 1996, 51:327-346
![Page 22: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/22.jpg)
Introduction
• Immunotoxins (Its) contain a targeting moiety for delivery and a toxic moiety for cytotoxicity.
• The toxins ( plant or bacterial toxin) are catalytic, fewer than 10 molecules in the cytosol of a target cell enough to be lethal.
Pharmacol. Ther. 1994, 63(3):209–234
![Page 23: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/23.jpg)
Schematic presentation of ligand-containing, shielded DNA complexes for tumor-targeted gene transfer
Journal of Controlled Release 2003, 91:173-181
![Page 24: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/24.jpg)
Targeting Moiety
• The targeting agents currently used to construct ITs are MoAbs, growth factors/cytokines, and soluble receptors.
• MoAbs are the most frequently used.
J. Clin. Immunol. 1992, 12:391–405
![Page 25: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/25.jpg)
Targeting Moiety
![Page 26: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/26.jpg)
Targeting Moiety
• Bispecific antibodies are novel targeting agents constructed by linking either chemically or genetically two different Fab fragment, one arm of which is directed against a target cell and the other against effector T cells or NK cells (e.g. anti-CD22/anti-CD3-RTA).
Blood 1993, 82:2224–34
![Page 27: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/27.jpg)
Toxin Moiety
• The most commonly used toxic moieties are derived from either bacteria[e.g. Pseudomonas exotoxin(PE) or diptheria toxin(DT)], or plants(e.g. abrin or ricin).
![Page 28: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/28.jpg)
Toxin Moiety
• Both types of toxins kill cells by inhibiting protein synthesis.– Plant toxins damage 28S rRNA, – Bacterial toxins inactivate EF-2
Ann. Rev. Immunol.
1996. 14:49–71
![Page 29: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/29.jpg)
Linkers
• For in vivo therapy, the toxic moiety of the IT must be coupled to the targeting ligand so that it remains stable in the blood and tissues but is separated from the targeting domain for effective translocation into the cytoplasm.
![Page 30: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/30.jpg)
Factors affecting the potency of an IT
• Binding affinity of the targeting moiety
• The density of the target Ag on the cell
• Naturally internalized or induced to do so.
• Intracellular routing
• May promote proliferation of target cell population
![Page 31: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/31.jpg)
Clinical trials
• The field of immnotoxin therapy is in its infancy. To date most ITs are just entering Phase II/III trials.
• Anti-IT antibodies were generated in most trials
![Page 32: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/32.jpg)
Conclusions
• For the therapy of cancer, ITs have yielded higher response rates in Phase I/II trials than some of the drugs used today.
• The generation of new constructs, combinatorial therapy, and in the case of cancer therapy, treatment of tumors that are amenable to IT-mediated killing will eventually result in effective treatment protocols.
![Page 33: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/33.jpg)
References
• Thrush GR., Lark LR., Clinchy BC., and Vitetta ES. Immunotoxins: An update. Ann. Rev. Immunol. 14: 49-71. 1996.
• Rustamzadeh E., Low WC., Vallera DA., and Hall WA. Immunotoxin therapy for CNS tumor. Journal of Neuro-oncology. 64: 101-116. 2003.
• Houshmand P., and Zlotnik A. Targeting tumor cells. Current Opinion in Cell Biology. 15: 640-644. 2003
• Ogris M., Walker G., Blessing T., Kircheis R., Wolschek M., and Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. Journal of Controlled Release. 91: 173-181. 2003
• Carlsson J., Aronsson EF., Hietala SO., Stigbrand T., and Tennvall J. Tumuor therapy with radionuclides: assessment of progress and problems. Radiotherapy and Oncology. 66: 107-117. 2003.
![Page 34: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/34.jpg)
Overview of Worldwide Drug Market
主講 : 蕭宏展
![Page 35: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/35.jpg)
Worldwide drug market sales
![Page 36: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/36.jpg)
2003 全球各區域藥品市場銷售額
區域銷售率
49%
28%
11%
8% 4%
北美
歐洲地區
日本
亞洲(不包含日本)、非洲、澳洲拉丁美洲
資料來源 :IMS Health
Total sales: around 5000 億美金
![Page 37: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/37.jpg)
全球十大藥物銷售
![Page 38: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/38.jpg)
Drug delivery system market
• 2002 年 worldwide sales: $41.1 billion• 2007 年 (e) worldwide sales: $66 billion
market share
Oralcontrolledrelease,53%
Polymer,10%
Pulmonary,19%
Transdermal, 10%
Transmucosal, 7%
others, 1%
Oral controlledreleasePolymer
Pulmonary
Transdermal
Transmucosal
others資料來源 :Front Line Strategic Consulting, Inc.
![Page 39: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/39.jpg)
Drug delivery system
Drug delivery system
Oral controlled release
Polymer Pulmonary Transdermal Transmucosal others
![Page 40: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/40.jpg)
Oral controlled release
• Sustained release or extended release drug• Compound is less susceptible to gastric degrada
tion
• Company:Elan Corp. and J&J Alza• Product:Nexium (R) Esomeprazole ($3302 millin
o) 、 Losec/Prilosec for treatment of gastric ulcer .
![Page 41: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/41.jpg)
Polymer
• A method of drug delivery in which a therapeutic is encapsulated in polymeric matrix and is slowly released at the site of action via diffusion and surface erosion.
• Inactive in the bloodstream
• Company: J&J Alza 、 Atrix• Product: PEG-Intron (pegylated interferon) for tr
eatment of chronic hepatitis C
![Page 42: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/42.jpg)
Pulmonary
• Improve patient compliance associated with the relative comfort and convenience of inhalers.
• Company: GlaxoSmithKline 、 Aerogen,Inc. 、 Nektar therapeutics
• Product: Aerodose® Insulin Inhaler 、 Seretide/Advair for treatment of asthma
![Page 43: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/43.jpg)
Transdermal
• Enable the passage of drug molecules across skin
• Lower dosing of medications result in few adverse side effects
• Company: J&J Alza 、 Noven Pharmaceutical
• Product: Catapres-TTS® (clonidine) for treatment of hypertension 、 NicoDerm® CQ® (nicotine) and Clear NicoDerm® CQ®
![Page 44: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/44.jpg)
Transmucosal
• Drug is introduced to the body across a mucous membrane which allows for the avoidance of the gastrointestinal tract and first pass liver metabolism and consequently allows the therapeutic to directly enter into circulation.
• Company: Nastech Pharmaceutical Co. 、 Pherin Pharmaceuticals
• Product:Premarin (estrogen) for treatment of symptom of menopause in women. Nasonex for treatment of specific allergy situation
![Page 45: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/45.jpg)
Major drug delivery company stock2004.5.4
Name Last changeALKERMES INC 15.42 +0.08 +0.52%
ANDRX GROUP 23.37 +0.53 +2.32%
ATRIX LABS 31.34 +1.18 +3.91%
BIOVAIL CORP 19.5 +0.50 +2.63%
CIMA LABS 31.95 +0.26 +0.82%
ELAN CORP PLC 22.03 +0.43 +1.99%
FLAMEL TECHNOL 27.94 +1.58 +5.99%
NASTECH PHARM 13.94 +0.06 +0.43%
NEKTAR THERAP 21.49 +1.22 +6.02%資料來源 :www.pharmcast.com
![Page 46: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/46.jpg)
ALZA
• 1968 ALZA Corporation was founded by Dr. Alejandro Zaffaroni in 1968 to realize his vision of sophisticated pharmaceutical products that precisely control the targeting, timing and dosing of therapeutic compounds.
![Page 47: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/47.jpg)
![Page 48: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/48.jpg)
Products
• OROS® Technology (11)• D-TRANS® Transdermal Technology (7)
Catapres-TTS® (clonidine), Duragesic® (fentanyl), Estrader
m® (estradiol), NicoDerm® (nicotine), Transderm-Nitro® (nitroglycerin)
• STEALTH® Liposomal Technology Doxil® (doxorubicin) an anti-cancer drug for the treatment of ovarian cancer
• DUROS® Implant Technology Viadur® (leuprolide acetate implant) treatment for prostate cancer
![Page 49: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/49.jpg)
![Page 50: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/50.jpg)
• 1995 Pfizer introduces Glucotrol XL®, its second once-daily product using ALZA's OROS® technology. It is introduced as an adjunct to diet for the control of hyperglycemia in patients with non-insulin dependent diabetes.
• 2001 ALZA Becomes a Member of the Johnson & Johnson Family of Companies
ALZA continues as a leader in the development and manufacture of pharmaceutical products incorporating its novel, proprietary drug delivery technologies for its partners in the global healthcare industry.
![Page 51: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/51.jpg)
![Page 52: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/52.jpg)
Biogen Idec (BIIB)
• In November 2003, Biogen Idec Inc. was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation.
• Core therapeutic areas are in neurology, oncology, and dermatology
![Page 53: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/53.jpg)
http://www.biospace.com/company_profile.cfm?CompanyID=1303
![Page 54: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/54.jpg)
http://www.biogenidec.com/site/025.html
![Page 55: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/55.jpg)
RITUXAN (R)
• RITUXAN (Rituximab): monoclonal antibody of CD20, for treatment of non-Hodgkin's lymphoma (NHL)
• Approved by FDA in November 1997
• Revenues for the first quarter of 2004: $542 million
• RITUXAN (R):$134 million , about 25% and in U.S. $362 million
![Page 56: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/56.jpg)
http://quote.money.cnn.com/quote/quote?symbols=biib&submit3.x=29&submit3.y=7
![Page 57: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/57.jpg)
Alkermes
• AIR® Pulmonary Drug Delivery System is a proprietary drug delivery technology composed of dry powders ideally suited for delivery to the lungs
![Page 58: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/58.jpg)
http://www.biospace.com/company_profile.cfm?CompanyID=1688
![Page 59: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/59.jpg)
• The unique AIR particle is a low density, porous structure with a geometric diameter of 5 - 30 µm *
* Particles with mass densities less than 0.4g/cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs’ natural clearance mechanisms until the inhaled particles delivered their therapeutic payload
David A. Edwards,* Justin Hanes,….,SCIENCE.VOL.276.20.JUNE.1997
![Page 60: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/60.jpg)
Ease of use
• Due to the inherent features of the AIR particles, a simple breath-actuated inhaler can be utilized without any additional power such as fans or motors.
• Alkermes® is developing a family of inhalers that combine compact size with low cost and ease of use
![Page 61: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/61.jpg)
![Page 62: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/62.jpg)
東洋製藥核心技術
1. 微脂體劑型2. 緩釋劑型3. 新藥開發
![Page 63: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/63.jpg)
微脂體• 1998 年取得第一項微脂體藥品許可證 Lipo-Dox 針劑 .
•全球第三家、台灣第一家核准 Doxorubicin微脂體劑型藥物
![Page 64: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/64.jpg)
長效舒緩劑型 --- 釋控技術•長效劑型愛舒可羅錠 Regrow( 長效型止咳錠 )取得新藥核可 ,在 1999 年上市 ,突破短效藥物需服用多次缺點 .
•長效化痰劑與解熱鎮痛劑 ,已進入臨床試驗階段
![Page 65: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/65.jpg)
2000 2001 2002 2003
營收(百萬元)
745 843 1245 1380
研發金額(百萬元)
63 106 143
員工總數(人 )
197 222 240
研發人員總數 (人 )
27 33 44
研發費用 /營收
8.4% 12.6 11.5%
研發人員 /員工總數
13.7% 14.9 16.7%
![Page 66: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/66.jpg)
東洋 (4105) 之經營績效 單位 : 億元
年度 92 91 90 89 88 87 86 85 84
期末股本 5 4 3 2 2 2 2 2 2
營業收入 13.8 12.4 8.4 7.5 7.0 5.4 4.3 4.7 3.4
每股營收( 元 )
27.5 33.8 30.4 31.3 29.2 25.3 23.3 23.7 17.2
稅前盈餘 2.6 2.5 1.1 0.5 0.5 0.0 0.1 0.2 0.2
稅前 EPS 5.2 6.8 4.0 2.1 2.1 0.0 0.5 1.0 1.0
稅後純益 2.4 2.1 1.0 0.4 0.4 0.0 0.1 0.1 0.2
稅後 EPS 4.8 5.7 3.6 1.7 1.7 0.0 0.5 0.5 1.0
資料來源 :日盛證券
![Page 67: Drug Delivery System 藥物投遞系統 生科系 04 級 黃玫璇 891672 生科系 04 級 許哲源 891659 生科系 04 級 蕭宏展 891631 生科系 04 級 楊淳竣 891625](https://reader030.vdocuments.site/reader030/viewer/2022012821/56649d805503460f94a63aaf/html5/thumbnails/67.jpg)
The End